Kate Oppegaard1, Carolyn S Harris1, Joosun Shin1, Steven M Paul1, Bruce A Cooper1, Jon D Levine2,3, Yvette P Conley4, Marilyn Hammer5, Frances Cartwright6, Fay Wright7, Laura Dunn8, Kord M Kober1, Christine Miaskowski9,10. 1. School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA. 2. School of Medicine, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA. 3. School of Dentistry, University of California, 513 Parnassus Ave, MSB, San Francisco, CA, 94117, USA. 4. School of Nursing, University of Pittsburgh, 440 Victoria Building, 3500 Victoria Street, Pittsburgh, PA, 15261, USA. 5. Dana-Farber Cancer Institute, 450 Brookline Avenue, LW523, Boston, MA, 02215, USA. 6. Department of Nursing, Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1068, New York, NY, 10029, USA. 7. Rory Meyers College of Nursing, New York University, 433 1st Avenue, Room 740, New York, NY, 10010, USA. 8. School of Medicine, Stanford University, 401 Quarry Road, Stanford, CA, 94305, USA. 9. School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA. chris.miaskowski@ucsf.edu. 10. School of Medicine, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA. chris.miaskowski@ucsf.edu.
Abstract
PURPOSE: The purposes of this study, in a sample of oncology patients (n = 1326) receiving chemotherapy, were to identify subgroups of patients with distinct anxiety profiles and evaluate for differences in demographic and clinical characteristics, stress and resilience measures, and severity of co-occurring symptoms (i.e., depression, sleep disturbance, attentional function, fatigue, pain). METHODS: Patients completed self-report questionnaires a total of six times over two cycles of chemotherapy. Severity of state anxiety was evaluated using the Spielberger State Anxiety Inventory and resilience was assessed using the Connor-Davidson Resilience Scale. Symptoms were assessed using the Center for Epidemiologic Studies Depression Scale, General Sleep Disturbance Scale, Lee Fatigue Scale, Attentional Function Index and Brief Pain Inventory. RESULTS: Based on the findings from the latent profile analysis that utilized the six assessments of state anxiety, 47.7% of the patients were classified as "Low," 28.3% as "Moderate," 19.5% as "High," and 4.5.% as "Very High." Anxiety levels remained relatively stable across the six timepoints. Compared to the Low class, membership in the Moderate, High, and Very High classes was associated with a number of characteristics (e.g., younger age, female gender, lower functional status, more comorbidities). Those patients with higher levels of anxiety reported higher levels of stress, lower levels of resilience, and increased severity of co-occurring symptoms. CONCLUSION: Our findings suggest that a substantial number of oncology patients may warrant referral to psychological services. Clinicians need to perform systematic assessments of anxiety, stress, and common symptoms and initiate appropriate interventions to enhance resilience and coping.
PURPOSE: The purposes of this study, in a sample of oncology patients (n = 1326) receiving chemotherapy, were to identify subgroups of patients with distinct anxiety profiles and evaluate for differences in demographic and clinical characteristics, stress and resilience measures, and severity of co-occurring symptoms (i.e., depression, sleep disturbance, attentional function, fatigue, pain). METHODS:Patients completed self-report questionnaires a total of six times over two cycles of chemotherapy. Severity of state anxiety was evaluated using the Spielberger State Anxiety Inventory and resilience was assessed using the Connor-Davidson Resilience Scale. Symptoms were assessed using the Center for Epidemiologic Studies Depression Scale, General Sleep Disturbance Scale, Lee Fatigue Scale, Attentional Function Index and Brief Pain Inventory. RESULTS: Based on the findings from the latent profile analysis that utilized the six assessments of state anxiety, 47.7% of the patients were classified as "Low," 28.3% as "Moderate," 19.5% as "High," and 4.5.% as "Very High." Anxiety levels remained relatively stable across the six timepoints. Compared to the Low class, membership in the Moderate, High, and Very High classes was associated with a number of characteristics (e.g., younger age, female gender, lower functional status, more comorbidities). Those patients with higher levels of anxiety reported higher levels of stress, lower levels of resilience, and increased severity of co-occurring symptoms. CONCLUSION: Our findings suggest that a substantial number of oncology patients may warrant referral to psychological services. Clinicians need to perform systematic assessments of anxiety, stress, and common symptoms and initiate appropriate interventions to enhance resilience and coping.
Authors: Cristiane Decat Bergerot; Hannah-Rose Mitchell; Kimlin Tam Ashing; Youngmee Kim Journal: Support Care Cancer Date: 2017-02-02 Impact factor: 3.603
Authors: W W T Lam; I Soong; T K Yau; K Y Wong; J Tsang; W Yeo; J Suen; W M Ho; W K Sze; A W Y Ng; A Kwong; D Suen; R Fielding Journal: Psychooncology Date: 2013-08-30 Impact factor: 3.894
Authors: Keyla Vargas-Román; C Lourdes Díaz-Rodríguez; Guillermo A Cañadas-De la Fuente; José Luis Gómez-Urquiza; Tania Ariza; E Inmaculada De la Fuente-Solana Journal: Health Psychol Date: 2020-03-26 Impact factor: 4.267
Authors: Mei Rosemary Fu; Melissa L McTernan; Jeanna M Qiu; Christine Miaskowski; Yvette P Conley; Eunjung Ko; Deborah Axelrod; Amber Guth; Tamara J Somers; Lisa J Wood; Yao Wang Journal: Integr Cancer Ther Date: 2022 Jan-Dec Impact factor: 3.077